Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630543 | 0.86 | SLC29A1 (0.41) | SLC29A1 | |
| SCHEMBL18630613 | 0.85 | ADORA3 (0.52) | SLC29A1TSHRTP53ADORA3TDP1 | |
| SCHEMBL23080201 | 0.82 | PAX8 (0.47) | TSHRNFKB1BLMPMP22ADORA3 | |
| SCHEMBL18630524 | 0.80 | ADORA3 (0.56) | SLC29A1CYP3A4TSHRNFKB1TP53 | |
| SCHEMBL1796050 | 0.79 | SLC29A1 (0.64) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL18630399 | 0.79 | ADORA2B (0.46) | SLC29A1TSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL18630522 | 0.78 | ADORA3 (0.56) | SLC29A1TSHRTP53ADORA3TDP1 | |
| SCHEMBL18631613 | 0.77 | ATG7 (0.44) | SLC29A1TSHRNFKB1ADORA3 | |
| SCHEMBL1795030 | 0.76 | SLC29A1 (0.64) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL18630476 | 0.76 | DNPH1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | SLC29A1 1761/4885CYP3A4 2208/4885TSHR 4073/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | SLC29A1 3671/4885CYP3A4 957/4885TSHR 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.